Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin
This article was originally published in The Pink Sheet Daily
Executive Summary
Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.